# NUP214

Source: https://onco.cc/targets/nup214/  
OnCo record `nup214` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NUP214 (Nuclear pore complex protein Nup214) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Renal cell carcinoma and 4 more.

## Summary

Part of the nuclear pore complex. Has a critical role in nucleocytoplasmic transport. May serve as a docking site in the receptor-mediated import of substrates across the nuclear pore complex.

Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.94, genetic association 0.28, somatic mutation 0.76). IntOGen calls it a driver in 2 cohorts (2 activating, 0 loss-of-function), covering Papillary Renal Cell Carcinoma, Small Intestinal Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: nucleoporin 214; Nuclear pore complex protein Nup214; D9S46E; N214
- Tags: cancer-genes-wave
- Symbol: NUP214
- Class: oncogene
- Biology: Part of the nuclear pore complex. Has a critical role in nucleocytoplasmic transport. May serve as a docking site in the receptor-mediated import of substrates across the nuclear pore complex. Location: Nucleus, nuclear pore complex (UniProt). Locus 9q34.13 (HGNC).
- Where found: Leukaemia: Open Targets association 0.60 with leukaemia (MONDO_0005059); Non-Hodgkin lymphoma: Open Targets association 0.59 with non-Hodgkin lymphoma (MONDO_0018908); Renal cell carcinoma: IntOGen driver in 1 cohort (PRCC); Small intestine cancer: IntOGen driver in 1 cohort (SIC); Myeloproliferative neoplasms: Open Targets association 0.53 with myeloproliferative neoplasm (MONDO_0020076); Papillary renal cell carcinoma: IntOGen driver in 1 cohort (PRCC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:8064: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8064
- UniProt P35658: https://www.uniprot.org/uniprotkb/P35658/entry
- NCBI Gene 8021: https://www.ncbi.nlm.nih.gov/gene/8021
- Ensembl ENSG00000126883: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000126883

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Papillary renal cell carcinoma](https://onco.cc/cancers/papillary-rcc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Small intestine cancer (small bowel adenocarcinoma)](https://onco.cc/cancers/small-bowel/)

---
JSON: https://onco.cc/api/v1/entities/nup214.json